Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01
Shots:
- Beijing Tide to receive up to $517.5M including up front- development- regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products
- Graviton to get exclusive development and commercialization rights for TDI01 in all territories (Ex- China)
- TDI01 is a targeted inhibitor of ROCK2 is currently being evaluated in a P-I study in the US for the treatment of IPF. The company expect to develop TDI01 for the treatment of various serious diseases
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
